Avalo Therapeutics, INC Form 4 insider transactions

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, reported the sale of 18,606 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, reported significant stock transactions on May 5th and 6th, 2026, under a Rule 10b5-1 trading plan.

Avalo Therapeutics Director Mitchell Chan executed a series of stock transactions under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics CFO Christopher Ryan Sullivan sold 16,915 shares of common stock via a pre-arranged 10b5-1 trading plan.

Avalo Therapeutics, Inc. reports insider transactions involving the acquisition and disposition of common stock and stock options by Chief Medical Officer Mittie Doyle.

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, has reported the sale of company stock through a pre-arranged trading plan.

Avalo Therapeutics, Inc. reports insider transactions involving common stock and stock options by Chief Medical Officer Mittie Doyle.

Avalo Therapeutics Director Rita Jain acquired 1,339 stock options, fully vested upon grant, with an exercise price of $14.93.

Avalo Therapeutics Director Samantha Truex converted 3,166 restricted stock units into common stock on March 28, 2026, increasing her direct beneficial ownership of common stock to 6,333 shares.

Avalo Therapeutics director Aaron Kantoff converted 3,166 restricted stock units into common stock as part of a pre-scheduled vesting event.

Avalo Therapeutics Director Gilla Kaplan filed a Form 4 detailing the future vesting of 3,166 restricted stock units into common stock on March 28, 2026.

Avalo Therapeutics CEO Garry Arthur reported the exercise of restricted stock units and subsequent sale of shares to cover taxes.

Avalo Therapeutics Director Mitchell Chan converted 3,166 restricted stock units into common stock as part of a pre-scheduled vesting event.

Avalo Therapeutics Director Jonathan Goldman converted 3,166 restricted stock units into common stock on March 28, 2026, as part of a routine vesting schedule.

Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, exercised stock options and subsequently sold a portion of the acquired common stock.

Avalo Therapeutics' Chief Legal Officer, Paul Varki, was granted 80,000 stock options with an exercise price of $17.64, vesting over four years.

Avalo Therapeutics' Chief Strategy Officer, Jennifer Riley, was granted 95,000 stock options with an exercise price of $17.64, vesting over four years.

Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, was granted 105,000 stock options with an exercise price of $17.64, aligning executive incentives with shareholder value.

Avalo Therapeutics' Chief Business Officer, Taylor Boyd, was granted 95,000 stock options with an exercise price of $17.64.

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, was granted 105,000 stock options with an exercise price of $17.64, vesting over four years.

Avalo Therapeutics' CEO, Garry Arthur Neil, was granted 286,000 stock options with an exercise price of $17.64, vesting over four years.

Avalo Therapeutics Director Rita Jain was granted 1,043 stock options with an exercise price of $18.16, fully vested on December 31, 2025.

Avalo Therapeutics Director Kevin Robert Lind acquired 848 stock options on December 31, 2025, under a Rule 10b5-1 plan.

Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, reported a disposition of 1,013 common shares for tax purposes, alongside a net increase in beneficial ownership to 3,622 shares, including those from an Employee Stock Purchase Plan.

Avalo Therapeutics' Chief Strategy Officer, Jennifer Riley, reported a planned disposition of 637 shares for tax purposes, retaining 2,655 shares acquired through an Employee Stock Purchase Plan.

Avalo Therapeutics' Chief Legal Officer, Paul Varki, disposed of 1,016 common shares at $4.10 each to cover tax withholding obligations.

Avalo Therapeutics' CFO, Christopher Sullivan, reported a disposition of 155 shares for tax purposes and an acquisition of 417 shares via the Employee Stock Purchase Plan, effective December 10, 2025.

Avalo Therapeutics Director Jonathan Goldman reported exercising stock options and subsequently selling common stock on November 14, 2025.

Avalo Therapeutics, Inc. granted Chief Business Officer Taylor Boyd 275,000 stock options with an exercise price of $12.96, vesting over four years.

Avalo Therapeutics, Inc. Director Kevin Robert Lind was granted 40,200 stock options with an exercise price of $12.96, vesting over three years.